Loading clinical trials...
Loading clinical trials...
A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere® (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients With Locally Advanced or Metastatic Breast Cancer After Failure to Prior Chemotherapy
Conditions
Interventions
Nanosomal Docetaxel Lipid Suspension (75 mg/m2)
Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
+1 more
Locations
4
United States
Columbus Regional Research Institute, LLC
Columbus, Georgia, United States
Cox Medical Center
Springfield, Missouri, United States
Gabrail Cancer Center
Canton, Ohio, United States
Kailash Cancer Hospital & Research Centre
Vadodara, Gujarat, India
Start Date
July 10, 2018
Primary Completion Date
May 31, 2025
Completion Date
December 31, 2025
Last Updated
March 21, 2025
NCT06681064
NCT05005403
NCT06547840
NCT06649331
NCT04585750
NCT07029399
Lead Sponsor
Jina Pharmaceuticals Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions